ADX71441 是一种口服有效的、可穿透血脑屏障的 GABAB 受体正变构调节剂,可增强 GABAB 受体处内源性 GABA 的活性(EC50 为 96 nM),并在功能上抑制腺苷转运体与 5-HT2B 受体,从而产生抗焦虑样、镇痛、肌肉松弛、降体温及抑制膀胱过度活动的作用,同时能降低急性自主活动水平、减少酒精和糖精的自主摄取、减轻应激诱导的神经元活化,并具有抗痛觉过敏活性。
产品编号: MS-Q01055 纯度: 98.63% CAS No.: 1207440-88-7 分子式: C19H15ClF2N4O4 分子量: 436.80
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价
200mg
询价
询价

产品描述

ADX71441 是一种口服有效的、可穿透血脑屏障的 GABAB 受体正变构调节剂,可增强 GABAB 受体处内源性 GABA 的活性(EC50 为 96 nM),并在功能上抑制腺苷转运体与 5-HT2B 受体,从而产生抗焦虑样、镇痛、肌肉松弛、降体温及抑制膀胱过度活动的作用,同时能降低急性自主活动水平、减少酒精和糖精的自主摄取、减轻应激诱导的神经元活化,并具有抗痛觉过敏活性。

生物实验数据

生物活性 ADX71441 is an orally active, blood-brain barrier-penetrant positive allosteric modulator of the GABAB receptor that enhances the activity of endogenous GABA at the GABAB receptor with an EC50 of 96 nM and functionally inhibits adenosine transporters and the 5-HT2B receptor, thereby producing anxiolytic-like, analgesic, muscle relaxant, hypothermic, and bladder overactivity-suppressing effects, while also reducing acute locomotor activity, decreasing voluntary intake of alcohol and saccharin, attenuating stress-induced neuronal activation, and exhibiting antihyperalgesic activity.
体外研究
(In Vitro)

ADX71441 (10-10 to 10-3 M; 180 s) 是重组人源 GABAB 受体的正向别构调节剂,可增强 GABA 诱导的钙动员,其 EC20 为 29 nM,无显著的直接激动剂活性,且能与该受体可逆性结合。
ADX71441 可增强内源性大鼠皮层 GABAB 受体处 GABA 诱导的 G 蛋白激活,其 EC50 为 53 nM,同时提升 GABA 的效价和效能。
ADX71441 可在内源性人皮质 GABAB 受体上增强 GABA 诱导的 G 蛋白激活,其 EC50 为 40 nM,能显著提升 GABA 的效能和效力。
ADX71441 对 GABAB 受体具有高度选择性,对 mGlu 受体无活性,仅在 5-HT2B 受体 (IC50 = 6.06 μM) 和腺苷转运体 (IC50 = 0.24 μM) 处表现出微弱的脱靶活性。

体内研究
(In Vivo)

ADX71441 (1-10 mg/kg; p.o.; 单次给药) 在小鼠埋珠试验中产生剂量依赖性的类抗焦虑作用,最低有效剂量为 3 mg/kg。
ADX71441 (1-10 mg/kg; p.o.; 单次给药) 在小鼠高架十字迷宫实验中产生剂量依赖性的类抗焦虑作用,最低有效剂量为 3 mg/kg。
ADX71441 (0.3-3 mg/kg; p.o.; 单次给药) 在大鼠高架十字迷宫实验中产生剂量依赖性的类抗焦虑作用,最低有效剂量为 3 mg/kg。
ADX71441 (30 mg/kg; p.o.; 单次给药) 在大鼠高架十字迷宫实验中,给药后 24 小时仍具有类抗焦虑功效。
ADX71441 (1-10 mg/kg; p.o.; 单次给药) 在小鼠醋酸扭体试验中产生剂量依赖性和时间依赖性的镇痛作用。
ADX71441 (10 mg/kg; p.o.; 单次给药) 在大鼠转棒试验中产生肌肉松弛作用。
ADX71441 (10 mg/kg; p.o.; 单次给药) 可降低经急性灌胃给药小鼠的自主活动能力。
ADX71441 (3-30 mg/kg; p.o.; 单次给药) 经急性口服给药后,可使大鼠的自发活动呈剂量依赖性降低,其最低有效剂量为 3 mg/kg。
ADX71441 (30 mg/kg; p.o.; 每日一次一共 7 天) 经亚慢性口服给药后,会使其在小鼠中产生的运动抑制效应出现耐受。
ADX71441 (3-30 mg/kg; p.o.; 单次给药) 可通过激活 GABAB 受体在小鼠中产生剂量依赖性的降温作用,其最低有效剂量为 10 mg/kg。
ADX71441 (3-30 mg/kg; p.o.; 单次给药) 在大鼠中产生剂量依赖性的短暂降温作用,最低有效剂量为 3 mg/kg。
ADX71441 (1-10 mg/kg; p.o.; 单次给药) 剂量依赖性地​减少 Furosemide (MS-I80061) 诱导的过度活跃膀胱 (OAB) 小鼠的尿频事件总数、总尿量、平均尿量,并增加首次排尿潜伏期。
ADX71441 (1-3 mg/kg; i.v.; 单次给药) 可快速改善 Acetic acid (MS-H89626) 诱导的豚鼠 OAB 的尿动力学参数。
ADX71441 (1-30 mg/kg; i.p.; 单次给药) 可剂量依赖性地使非成瘾雄性 Wistar 大鼠的 20% 酒精自主摄取量降低。
ADX71441 (1-3 mg/kg; i.p.; 单次给药) 在酒精依赖的雄性 Wistar 大鼠中表现出更强的减少酒精自服行为的效力。
ADX71441 (3-10 mg/kg; i.p.; 单次给药) 可强效阻断经训练能够自主摄酒的雄性 Wistar 大鼠中由线索诱导和应激诱导的类复吸饮酒行为。
ADX71441 (3 mg/kg; i.p.; 单次给药) 可减轻雄性 Wistar 大鼠中与应激诱导的复吸样觅酒行为相关的脑区网络 (伏隔核壳部、中央杏仁核、中缝背核和内侧前额叶皮层) 内的应激诱导神经元激活。
ADX71441 (0.3-15 mg/kg; p.o.; 每日一次共 7 天) 在 Sodium iodoacetate (MS-X68601) 诱导的大鼠骨关节炎模型中表现出剂量依赖性的抗痛觉过敏功效。
ADX71441 (1-10 mg/kg; p.o.; 单次给药) 在大鼠上具有肌肉松弛作用。

Animal Model: C57Bl6/J (male, adult, 24-30g)
Dosage: 1 mg/kg; 3 mg/kg; 10 mg/kg
Administration: p.o.; single dose; 60 minutes pre-test
Result: Showed no effect at 1 mg/kg.
Produced a ~55% reduction in buried marbles at 3 mg/kg.
Fully suppressed burying behavior at 10 mg/kg.
Reached mean plasma concentrations of 144 ng/mL (1 mg/kg), 341 ng/mL (3 mg/kg), and 629 ng/mL (10 mg/kg) at end of experiment.\nShowed no effect at 1 mg/kg.
Produced ~2-fold increases in open arm entries at 3 mg/kg and 10 mg/kg.
Produced a ~2-fold increase in time spent on open arms at 3 mg/kg, and an almost 3-fold increase at 10 mg/kg.
Showed no effect on closed arm exploration.
Reached mean plasma concentrations of 168 ng/mL (1 mg/kg), 399 ng/mL (3 mg/kg), and 688 ng/mL (10 mg/kg) at end of experiment.
Animal Model: Sprague-Dawley (male, adult, 250-350g)
Dosage: 0.3 mg/kg; 1 mg/kg; 3 mg/kg
Administration: p.o.; single dose; 60 minutes pre-test
Result: Showed no effect at 0.3 mg/kg and 1 mg/kg.
Produced more than 3-fold increases in open arm entries and more than 4-fold increases in time spent on open arms at 3 mg/kg.
Showed no effect on closed arm exploration.
Reached mean plasma concentrations of 46 ng/mL (1 mg/kg), 171 ng/mL (3 mg/kg) at end of experiment.
Animal Model: Sprague-Dawley (male, adult, 250-350g)
Dosage: 1 mg/kg; 3 mg/kg; 10 mg/kg; 30 mg/kg
Administration: p.o.; single dose; 24 hours pre-test
Result: Showed no effect at 1 mg/kg and 3 mg/kg.
Showed a trend toward reduced open arm entries at 10 mg/kg.
Produced almost 4-fold increases in open arm entries and almost 4-fold increases in time spent on open arms at 30 mg/kg.
Showed no effect on closed arm entries.
Reached mean brain concentrations of 40 ng/g (1 mg/kg), 107 ng/g (3 mg/kg), 427 ng/g (10 mg/kg), and 1014 ng/g (30 mg/kg); mean plasma concentrations of 11 ng/mL (1 mg/kg), 52 ng/mL (3 mg/kg), 321 ng/mL (10 mg/kg), and 898 ng/mL (30 mg/kg) at end of experiment.
Animal Model: C57Bl6/J (male, adult, 24-30g; separate cohort from SLAC, Shanghai, China)
Dosage: 1 mg/kg; 3 mg/kg; 10 mg/kg
Administration: p.o.; single dose; 70 minutes pre-test (dose-response); 1, 2, 4 hours pre-test (time-course)
Result: Showed no effect at 1 mg/kg in dose-response study.
Produced a 55% reduction in writhes at 3 mg/kg, and an almost 90% reduction at 10 mg/kg in dose-response study.
Produced an ~80% reduction in writhes at 1 hour post-treatment, ~60% reduction at 2 hours, and ~25% reduction (trend) at 4 hours with 10 mg/kg in time-course study.
Reached mean plasma concentrations of 562 ng/mL (1 hour), 566 ng/mL (2 hours), and 343 ng/mL (4 hours) in time-course study.
Animal Model: Sprague-Dawley (male, adult, 250-350g)
Dosage: 1 mg/kg; 3 mg/kg; 10 mg/kg
Administration: p.o.; single dose; measured at 60, 120, 180 minutes post-treatment
Result: Showed no effect at 1 mg/kg and 3 mg/kg across all time points.
Reduced time on rotarod by approximately 50% at all time points at 10 mg/kg.
Animal Model: C57Bl6/J (male, adult, 24-30g)
Dosage: 1 mg/kg; 3 mg/kg; 10 mg/kg
Administration: p.o.; single dose; 60 minutes pre-test; monitored for 60 minutes
Result: Showed no effect at 1 mg/kg and 3 mg/kg.
Produced a ~40% reduction in total distance travelled at 10 mg/kg.
Animal Model: Sprague-Dawley (male, adult, 250-350g)
Dosage: 1 mg/kg; 3 mg/kg; 10 mg/kg; 30 mg/kg
Administration: p.o.; single dose; 60 minutes pre-test; monitored for 60 minutes
Result: Showed no effect at 1 mg/kg.
Produced an ~50% reduction in total distance travelled at 3 mg/kg, ~85% reduction at 10 mg/kg, and almost 100% reduction at 30 mg/kg.
Animal Model: C57Bl6/J (male, adult, 24-30g; cohort from Charles River Laboratories, Wilmington, MA)
Dosage: 10 mg/kg; 30 mg/kg
Administration: p.o.; once daily for 7 days plus acute dose on day 8; 60 minutes pre-test on day 8; monitored for 60 minutes
Result: Showed no reduction in locomotor activity (total distance travelled or rearing) with acute 30 mg/kg dose in mice with sub-chronic 30 mg/kg treatment history.
Produced an ~50% reduction in total distance travelled and ~90% reduction in rears with acute 30 mg/kg dose, and no effect with acute 10 mg/kg dose in vehicle-treated mice.
Animal Model: C57Bl6/J (male, adult, 24-30g; cohort from Janvier, Le Genest Saint Isle, France)
Dosage: 3 mg/kg; 10 mg/kg; 30 mg/kg
Administration: p.o.; single dose; measured at 1, 2, 4 hours post-treatment (acute); p.o. 30 mg/kg plus oral CGP63360 30 minutes later (target engagement)
Result: Showed no effect at 3 mg/kg in acute dose-response study.
Produced a 1.5°C reduction at 1 and 2 hours at 10 mg/kg, and a ~3°C reduction at 1 and 2 hours plus 1.77°C reduction at 4 hours at 30 mg/kg in acute dose-response study.
Had hypothermic effects dose-dependently reversed by CGP63360 in target engagement study; 3 mg/kg CGP63360 returned body temperature to normal at 2 and 4 hours post-ADX71441 treatment.
Animal Model: Sprague-Dawley (male, adult, 250-350g)
Dosage: 1 mg/kg; 3 mg/kg; 10 mg/kg; 30 mg/kg
Administration: p.o.; single dose; measured at 1, 2, 4, 20 hours post-treatment
Result: Showed no effect at 1 mg/kg.
Produced 0.5-1.2°C reductions at 1, 2, and 4 hours at 3 mg/kg and 10 mg/kg.
Produced 1.4-1.8°C reductions at 1, 2, and 4 hours at 30 mg/kg.
Showed no effect at 20 hours post-treatment across all doses.
Animal Model: C57Bl6/J (adult male, 24-30 g, overhydrated with water and challenged with furosemide to induce bladder overactivity)
Dosage: 1 mg/kg; 3 mg/kg; 10 mg/kg
Administration: p.o.; single dose
Result: Produced a 70% reduction in total urinary events, a more than threefold increase in latency to the first urinary event, a 55% reduction in total urinary volume, and an approximately 65% reduction in average urinary volume compared to vehicle-treated mice at 10 mg/kg.
Normalized urinary parameters to levels not significantly different from intact untreated controls for number of urinary events, latency to first event, and average urinary volume at 3 mg/kg and 10 mg/kg.
Normalized total urinary volume to levels not significantly different from intact untreated controls at 10 mg/kg.
Achieved plasma concentrations of 101 ng/mL (1 mg/kg), 208 ng/mL (3 mg/kg), and 652 ng/mL (10 mg/kg), corresponding to unbound plasma concentration/EC50 ratios of 0.36, 0.74, and 2.31 respectively.
Animal Model: Dunkin Hartley (adult female, 290-370 g, OAB induced by intravesical infusion of 0.2% acetic acid)
Dosage: 1 mg/kg; 3 mg/kg
Administration: i.v.; single bolus dose
Result: Significantly increased intercontraction interval and bladder capacity at 1 mg/kg and 3 mg/kg 0-15 minutes post-administration.
Significantly reduced micturition frequency compared to vehicle at 1 mg/kg 0-15 minutes post-administration.
Significantly increased threshold pressure compared to vehicle at 3 mg/kg 0-15 minutes post-administration.
Completely inhibited the micturition reflex, inducing overflow incontinence, in 5 out of 10 animals at 3 mg/kg.
Achieved plasma concentrations of 67 ng/mL (1 mg/kg) and 195 ng/mL (3 mg/kg), corresponding to unbound plasma concentration/EC50 ratios of 0.3 and 0.9 respectively.
Animal Model: Wistar rats (adult male, 200-225g at study initiation, trained to self-administer 20% alcohol on FR2 schedule)
Dosage: 1 mg/kg; 3 mg/kg; 10 mg/kg; 30 mg/kg
Administration: i.p.
Result: Showed no significant reduction in alcohol reinforcers earned or active lever presses, and no effect on locomotor activity at 1 mg/kg.
Produced statistically significant reduction in alcohol reinforcers earned and active lever presses, no alteration to locomotor activity, and potent reduction in alcohol breakpoints at 3 mg/kg.
Produced statistically significant reduction in alcohol reinforcers earned and active lever presses, no alteration to locomotor activity, and potent reduction in alcohol breakpoints at 10 mg/kg.
Produced statistically significant reduction in alcohol reinforcers earned and active lever presses, and significant reduction in locomotor activity at 30 mg/kg.
Animal Model: Wistar rats (adult male, 200-225g at study initiation; alcohol-dependent via chronic intermittent 14-hour daily alcohol vapor exposure for 8 weeks; non-dependent control exposed to normal air)
Dosage: 1 mg/kg; 3 mg/kg
Administration: i.p.
Result: Significantly decreased alcohol reinforcers earned and active lever presses in alcohol-dependent rats but had no significant effect in non-dependent rats at 1 mg/kg.
Significantly decreased alcohol reinforcers earned and active lever presses in both alcohol-dependent and non-dependent rats at 3 mg/kg.
...(内容过长已截断)
性状 固体
颜色 White to off-white

化学信息

分子量 436.80
分子式 C19H15ClF2N4O4
CAS No. 1207440-88-7

储存&溶解度

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础